These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 30721720)

  • 61. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
    Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
    JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity.
    Valeriani M; Carnevale A; Osti MF; Minniti G; De Sanctis V; Agolli L; Bracci S; Enrici RM
    Tumori; 2013; 99(4):474-9. PubMed ID: 24326835
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
    Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
    Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer.
    Henderson RH; Bryant CM; Nichols RC; Mendenhall WM; Hoppe BS; Su Z; Morris CG; Mendenhall NP
    Acta Oncol; 2022 Apr; 61(4):468-477. PubMed ID: 34965846
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    Hoffman KE; Voong KR; Levy LB; Allen PK; Choi S; Schlembach PJ; Lee AK; McGuire SE; Nguyen Q; Pugh TJ; Frank SJ; Kudchadker RJ; Du W; Kuban DA
    J Clin Oncol; 2018 Oct; 36(29):2943-2949. PubMed ID: 30106637
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis.
    Yao L; Shou J; Wang S; Song Y; Fang H; Lu N; Tang Y; Chen B; Qi S; Yang Y; Jing H; Jin J; Yu Z; Li Y; Liu Y
    Radiat Oncol; 2020 Oct; 15(1):231. PubMed ID: 33008404
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
    Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
    In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The 5-year outcomes of moderately hypofractionated radiotherapy (66 Gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study.
    Hashimoto Y; Motegi A; Akimoto T; Mitsuhashi N; Iizuka J; Tanabe K; Ishii Y; Kono S; Izumi S; Karasawa K
    Int J Clin Oncol; 2018 Feb; 23(1):165-172. PubMed ID: 28758177
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
    Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
    Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
    Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP
    Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT.
    Guckenberger M; Lawrenz I; Flentje M
    Strahlenther Onkol; 2014 Jan; 190(1):48-53. PubMed ID: 24196279
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
    de Vries KC; Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):108-115. PubMed ID: 31593756
    [TBL] [Abstract][Full Text] [Related]  

  • 80. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
    Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.